We report a 54-year-old woman who received interferon alpha for haematological relapse of Ph-positive CML, 7 years after allogeneic BMT from an HLA-identical brother. Eighteen months after relapse, cytogenetic and molecular remission was achieved. She received interferon therapy for 25 months and it was discontinued when she developed skin lesions on her face and trunk, dysphagia and fever with respiratory failure and bilateral patchy airspace consolidation of the lung without microbiologic findings. Histologic features showed discoid lupus erythematosis, oesophagitis with pseudomembranes and a mixed pattern of lymphocytic bronchiolitis involving the alveoli and interstitial spaces all compatible with chronic GVHD. The patient was commenced on immunosuppressive therapy with complete clinical and radiological resolution. The available evidence supports an atypical presentation of chronic GVHD and suggests a role for interferon alpha in the pathogenesis of GVHD. To the best of our knowledge, this is the first case reported of severe chronic GVHD occurring during the course of interferon therapy for relapsed CML. Bone Marrow Transplantation (2001) 27, 85-87.
Immunotherapy using interferon alpha (IFN) both with and without donor lymphocyte infusion (DLI) has become a treatment option direction for patients relapsing after allogeneic bone marrow transplantation (BMT) for chronic myeloid leukaemia (CML). Prolonged cytogenetic responses have been reported in a large number of patients. [1] [2] [3] [4] [5] [6] Remissions after DLI therapy can be complicated by severe acute and chronic graft-versus-host disease (GVHD) contributing to poor performance status or increased mortality in high risk patients. [1] [2] [3] By contrast, treatment based on IFN alone results in less toxicity and induces durable cytogenetic responses but only occasional molecular remission. [4] [5] [6] Chronic GVHD is a pleiomorphic syndrome which varies in time of onset, organ systems involved and rate of progression, and its manifestations commonly resemble various autoimmune diseases. 7, 8 It is a major cause of late morbidity and mortality following allogeneic BMT and DLI, but rarely documented outside these settings.
We report a patient who was treated with IFN alone for CML which relapsed post BMT. Cytogenetic and molecular remission was obtained, but the course of the IFN therapy was complicated by late development of severe chronic GVHD with involvement of the skin, oesophagus and lung, which resolved after immunosuppressive treatment.
Case report
A 44-year-old woman was diagnosed with Ph-positive CML in chronic phase in June 1989, Sokal score 3.0. She was treated first with hydroxyurea and subsequently with melphalan due to uncontrolled thrombocytosis. In March 1990, she underwent allogeneic BMT from an HLA-identical brother. During pretransplant screening, she was found to be HCV positive. The conditioning regimen consisted of cyclophosphamide 60 mg/kg × 2 days and TBI (13.2 Gy). Cyclosporin A (CsA, 3 mg/kg) was used as GVHD prophylaxis. The transplant course was uneventful and engraftment was documented on day +11 (PMN Ͼ0.5 × 10 9 /l, and platelets Ͼ30 × 10 9 /l). She experienced grade I skin acute GVHD, which was well controlled with CsA and steroids. Nine months post BMT she developed limited chronic GVHD of the skin, sicca syndrome and a transient elevation in hepatic enzymes which resolved with oral steroids after 6 months. Seven years post BMT, in July 1997, cytogenetic and haematological relapse was identified by detection of residual disease by RT-PCR of p210 BCR-ABL and haematopoietic chimaerism by minisatellite PCR. Treatment with daily IFN was started at a dose of 6 × 10 6 MU. Six months later a stable cytogenetic remission was achieved with absence of the BCR-ABL transcript 1 year after the Ph chromosome disappeared ( Figure 1 ). Prior to achieving molecular remission, she developed an episode of seropositive rheumatoid arthritis (RA) which was treated with steroids and methotrexate (MTX). In June 1999, she remained in cytogenetic and molecular remission and was still receiving IFN therapy. However, she developed erythematous skin lesions on her face, trunk, arms and neck associated with severe dysphagia. Histology of a skin biopsy revealed discoid lupus erythematosis, while endoscopic exploration demonstrated oesophagitis with pseudomembranes. No infectious pathogens were detected in the oesophageal biopsies. The IFN was stopped and she was started on intravenous acyclovir and nutritional support. However, her symptoms worsened with the onset of fever and bilateral lung infiltrates were present on chest X-ray. Lung CT imaging showed bilateral patchy airspace consolidation and nodular opacities. All microbiological tests were persistently negative although amphotericin B, and trimetroprim i.v. were added empirically. Respiratory distress syndrome developed she required intubation and mechanical ventilation. Bronchoalveolar lavage and transbronchial biopsy showed no mycotic or microbiologic features. Open lung biopsy was performed, and showed a mixed pattern of inflammation involving the alveoli and interstitial spaces with a lymphocytic infiltrate compatible with the histological spectrum of chronic pulmonary GVHD. These features therefore supported a diagnosis of chronic GVHD, and immunosuppressive therapy was started with CsA and steroids. Rapid improvement in her respiratory symptoms occurred, with normalization of oral intake and disappearance of the skin lesions and radiological changes. She was discharged on CsA therapy for 4 months, with complete resolution of symptoms. Three months later she remains well on no treatment and with normal pulmonary function.
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Discussion
Interferon (IFN) has shown antiproliferative activity in several malignant haematological diseases and may be of benefit for patients relapsing after BMT. Adverse side-effects such as myelosuppression, anorexia, weight loss and fatigue are common and can lead to discontinuation or dose reduction. Additionally, there are occasional reports in the literature of acute GVHD associated with IFN therapy outside the allo-transplant setting 9, 10 or during treatment for relapse after a BM allograft for haematological malignancies. [11] [12] [13] However, larger reports [4] [5] [6] have not documented any relationship between IFN therapy and GVHD. In only one series, 14 where IFN was administered in patients considered to be at high risk of relapse post BMT, was de novo acute GVHD described in three of 11 cases and presumed to be induced by IFN therapy.
Thus, it is currently unclear whether or not the use of IFN is associated with an increased incidence or severity of acute GVHD when it is given in the allogeneic transplant setting. 13 Our patient had not shown any signs of acute GVHD during IFN therapy, but the clinical features, imaging studies, negative microbiologic data and histologic findings seemed to confirm chronic GVHD. This case is thus unique, since it is the first report of an atypical clinical presentation of severe chronic GVHD in a patient in molecular remission with complete donor chimaerism following IFN therapy for relapsed CML. Moreover, the timing of events in this case suggest that the IFN was associated with the occurrence of chronic GVHD. Both IFN withdrawal and immunosuppressive therapy resulted in a rapid improvement, and finally complete resolution of the clinical syndrome, which further reinforces the possible pathogenic role of IFN.
Firstly, we questioned whether the clinical pictures could have been a direct side-effect of IFN therapy, since its capability to precipitate or exacerbate autoimmune disorders in patients with concomitant HCV infection is well recognised and may include lupus-like syndromes and seropositive rheumatoid arthritis. 15 Pneumonitis has been also described during IFN treatment for chronic hepatitis C, but usually showed an interstitial pattern. 15 However, we considered that the clinical picture as a sole side-effect of IFN therapy was unlikely since the histologic features were identical to those of classical chronic GVHD, and included oesophageal involvement, which has not been described in the HCV setting nor with IFN therapy.
This patient developed an unusual form of chronic GVHD which was aggressive and very late in onset, with multi-organ involvement, and which may have resulted from immunological damage increased by IFN therapy. Interferons are known to have a strong immunoregulatory effect: alpha, beta and gamma interferons enhance the expression of class I MHC antigens and gamma interferon is also able to induce class II expression in certain cells and adhesion molecules activation involved in the initial amplification of allogeneic responses. 16 They increase the activity of natural killer cells which have been reported to be mediators of tissue damage in GVHD, as well as stimulate macrophages and lymphocytes, thus potentially enhancing cell-mediated cytotoxicity and an immunemediated antileukaemic action. 17 There is also accumulating evidence that IFN and other cytokines play a role in the pathogenesis of GVHD. Levels of alpha, beta and gamma interferons have been documented to rise in association with the onset of acute and chronic GVHD and they are also produced locally in the target organs for GVHD 18, 19 in animal models, implying that similar changes may occur in humans.
In conclusion, this patient had an atypical presentation of aggressive and extensive chronic GVHD of late onset, potentially induced or aggravated by exogenous IFN.
